
Amazon has reached a final deal with EU antitrust regulators over concerns its use of data undermined rivals, in a move that will close two of the most high-profile probes in Brussels.
The US ecommerce group has committed to increasing the visibility of rival products by giving them equal treatment on Amazon’s “buy box”, which generates the majority of purchases on the site. It will also create an alternative featured offer for those buyers where speed of delivery is less important.
Related: Amazon May Soon Settle With EU Antitrust Regulators
The European Commission plans to announce the deal on December 20, according to four people with direct knowledge of the timing. However, they warned the date could still change at the last minute.
The commitments, which are set to remain in force for five years, have been “market tested” with rivals and agreed with EU officials, these people said. “There’s very little to discuss,” a person with knowledge of the process said.
The move represents a win for the EU as it will serve as a blueprint for the tech group’s compliance with the new Digital Markets Act, a piece of legislation aimed at curbing the power of Big Tech.
It also means Amazon will avoid formal charges of breaking EU law and a large fine of up to 10 percent of global revenues. The DMA is the first big overhaul of the rules governing technology groups in more than two decades.
It sets out new obligations on large online platforms to give equal treatment to data, banning so-called self-preferencing whereby a company ranks its products ahead of rivals on its own marketplace.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas